Literature DB >> 6809960

Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

S A Brosman.   

Abstract

A randomized study was done on 49 patients with a history of recurrent superficial transitional cell carcinoma of the bladder to determine if the frequency of tumor recurrence could be lessened. The patients were treated with 6 weekly instillations of Tice strain bacillus Calmette-Guerin or thio-tepa, followed by instillations every 2 weeks for 3 months and every month until a recurrence developed or the patients had been treated for 2 years. Twelve additional patients who had previously failed on thio-tepa were placed on the bacillus Calmette-Guerin protocol. There have been no recurrences in the bacillus Calmette-Guerin group, while 9 patients (40 per cent) in the thio-tepa group suffered recurrences. All of the patients treated with bacillus Calmette-Guerin had symptoms of bladder irritability after each instillation. The same type of irritability occurred in 7 patients (25 per cent) in the thio-tepa group. Severe complications occurred in 11 patients treated with bacillus Calmette-Guerin (28 per cent), 4 of whom required hospitalization. Another 12 patients with visible transitional cell carcinoma were treated with weekly instillations of bacillus Calmette-Guerin. Of these patients 6 had total resolution after 18 weekly instillations and 2 had no detectable tumor after 24 weeks of therapy. Two patients were free of tumor after 6 instillations. Of 7 patients with carcinoma in situ treated with weekly instillations of bacillus Calmette-Guerin 5 had complete resolution of the cellular atypia after 18 weeks of therapy. These studies confirm and extend those of others by demonstrating that bladder instillations of bacillus Calmette-Guerin are effective in reducing the recurrence rate in patients with superficial bladder tumor and can eliminate existing tumor in some patients. Symptoms of bladder irritability occur to a varying extent in every patient, and severe systemic toxicity occurred in 28 per cent of the patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6809960     DOI: 10.1016/s0022-5347(17)52736-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  42 in total

1.  Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.

Authors:  Argyrios Siatelis; Dimitra P Houhoula; Joseph Papaparaskevas; Dimitrios Delakas; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Long-term BCG immune therapy of superficial bladder tumours.

Authors:  L Somogyi; A Szántó; L Polyák; F Baranyay; M Drinóczy
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

3.  Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer.

Authors:  M D Melekos; A Pantazakos; S Markou; C Skopa; A Athanassopoulos; G Barbalias
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

4.  Local BCG therapy of superficial bladder tumours.

Authors:  J Kondás; E Szentgyörgyi; L Szecsö; G Kondér
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

5.  Clinical studies on bladder tumor-associated antigen in serum of patients with bladder cancer by using monoclonal antibody and sandwich ELISA.

Authors:  S S Zhu; Y C Zhang; R Z Hu; Z Q Ye; C J Li; Q A Lin
Journal:  J Tongji Med Univ       Date:  1990

6.  Intravesical treatment of severe bacillus Calmette-Guerin cystitis.

Authors:  J Palou; L Rodríguez-Villamil; A Andreu-Crespo; J Salvador-Bayarri; J Vicente-Rodríguez
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

7.  The effects of intravesical and intradermal application of a new B.C.G. on the dog bladder.

Authors:  A P vd Meijden; P A Steerenberg; W H de Jong; M J Bogman; W F Feitz; B T Hendriks; F M Debruyne; E J Ruitenberg
Journal:  Urol Res       Date:  1986

Review 8.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

9.  Bacillus Calmette-Guérin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients.

Authors:  P Conti; M Reale; M Nicolai; R C Barbacane; F C Placido; R Iantorno; R Tenaglia
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

10.  The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience.

Authors:  Lamont J Barlow; James M McKiernan; Mitchell C Benson
Journal:  World J Urol       Date:  2009-02-13       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.